EGFR and non-small cell lung carcinoma: Recently, the FLAURA trial demonstrated the superiority of osimertinib over gefitinib or erlotinib in the first-line setting of EGFR-mutant NSCLC as shown in an improved mOS and mPFS for advanced EGFR mutant NSCLC [30,31].